AU Patent

AU2016204119B2 — Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias

Assigned to Celgene Corp · Expires 2017-12-21 · 8y expired

What this patent protects

A method of treating leukemia in a human, which comprises administering to a human in need thereof a therapeutically effective amount of 3-(4-amino-l-oxo-1,3-dihydro-isoindol-2 5 yl)-piperidine-2,6-dione, wherein the leukemia is acute lymphoblastic leukemia, or acute myelogenous …

USPTO Abstract

A method of treating leukemia in a human, which comprises administering to a human in need thereof a therapeutically effective amount of 3-(4-amino-l-oxo-1,3-dihydro-isoindol-2 5 yl)-piperidine-2,6-dione, wherein the leukemia is acute lymphoblastic leukemia, or acute myelogenous leukemia.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016204119B2
Jurisdiction
AU
Classification
—
Expires
2017-12-21
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.